DekaBank Deutsche Girozentrale’s Edgewise Therapeutics EWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.52M Hold
80,000
﹤0.01% 666
2026
Q1
$2.57M Hold
80,000
﹤0.01% 665
2025
Q4
$1.56M Hold
80,000
﹤0.01% 804
2025
Q3
$1.55M Hold
80,000
﹤0.01% 796
2025
Q2
$1.56M Hold
80,000
﹤0.01% 789
2025
Q1
$1.44M Hold
80,000
﹤0.01% 783
2024
Q4
$1.36M Hold
80,000
﹤0.01% 815
2024
Q3
$1.44M Hold
80,000
﹤0.01% 827
2024
Q2
$1.44M Hold
80,000
﹤0.01% 819
2024
Q1
$1.44M Hold
80,000
﹤0.01% 811
2023
Q4
$920K Hold
80,000
﹤0.01% 916
2023
Q3
$471K Hold
80,000
﹤0.01% 1026
2023
Q2
$602K Buy
80,000
+50,000
+167% +$422K ﹤0.01% 993
2023
Q1
$200K Hold
30,000
﹤0.01% 1178
2022
Q4
$265K Hold
30,000
﹤0.01% 1177
2022
Q3
$291K Buy
30,000
+10,200
+52% +$103K ﹤0.01% 1159
2022
Q2
$153K Hold
19,800
﹤0.01% 1237
2022
Q1
$183K Buy
19,800
+1,800
+10% +$23.2K ﹤0.01% 1224
2021
Q4
$269K Buy
+18,000
New +$324K ﹤0.01% 1215

Other funds holding EWTX

DekaBank Deutsche Girozentrale's EWTX Position: Q2 2026 in Review

DekaBank Deutsche Girozentrale held its Edgewise Therapeutics (EWTX) position steady in Q2 2026 at 80,000 shares worth $2.52M. The position accounts for ﹤0.01% of the portfolio, ranked #666.

DekaBank Deutsche Girozentrale first reported a position in EWTX in Q4 2021 and has held it in 19 quarters since. The position peaked at $2.57M in Q1 2026. 73 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • DekaBank Deutsche Girozentrale held 80,000 shares of Edgewise Therapeutics worth $2.52M as of Q2 2026.
  • DekaBank Deutsche Girozentrale left its Edgewise Therapeutics share count unchanged in Q2 2026.
  • Edgewise Therapeutics made up ﹤0.01% of DekaBank Deutsche Girozentrale's portfolio in Q2 2026, its #666 holding.
  • DekaBank Deutsche Girozentrale first reported a position in Edgewise Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • DekaBank Deutsche Girozentrale's Edgewise Therapeutics position peaked at $2.57M in Q1 2026.
  • 73 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2026, filed 5 Aug 2026.